A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Vasu, Sumithira, Altman, Jessica K, Uy, Geoffrey L, Tallman, Martin S, Gojo, Ivana, Lozanski, Gerard, Burkard, Ute, Osswald, Annika, James, Pamela, Rüter, Björn, Blum, William
Published in Haematologica (Roma) (01.03.2022)
Published in Haematologica (Roma) (01.03.2022)
Get full text
Journal Article
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
Komrokji, Rami S, Carraway, Hetty E, Germing, Ulrich, Wermke, Martin, Zeidan, Amer M, Fu, Eric, Rüter, Björn, Burkard, Ute, Osswald, Annika, Foran, James M
Published in Haematologica (Roma) (01.11.2022)
Published in Haematologica (Roma) (01.11.2022)
Get full text
Journal Article
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
Fiedler, Walter, Montesinos, Pau, Schliemann, Christoph, Middeke, Jan, Vasu, Sumithira, Scholz, Christian W, Esteve, Jordi, Mondal, Shoubhik, Rüter, Björn, Burkard, Ute, Osswald, Annika, Blum, William
Published in Haematologica (Roma) (01.12.2022)
Published in Haematologica (Roma) (01.12.2022)
Get full text
Journal Article
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Kroschinsky, Frank, Middeke, Jan Moritz, Janz, Martin, Lenz, Georg, Witzens-Harig, Mathias, Bouabdallah, Reda, La Rosée, Paul, Viardot, Andreas, Salles, Gilles, Kim, Seok Jin, Kim, Tae Min, Ottmann, Oliver, Chromik, Joerg, Quinson, Anne-Marie, von Wangenheim, Ute, Burkard, Ute, Berk, Andreas, Schmitz, Norbert
Published in Investigational new drugs (01.10.2020)
Published in Investigational new drugs (01.10.2020)
Get full text
Journal Article
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Kroschinsky, Frank, Middeke, Jan Moritz, Janz, Martin, Lenz, Georg, Witzens-Harig, Mathias, Bouabdallah, Reda, La Rosée, Paul, Viardot, Andreas, Salles, Gilles, Kim, Seok Jin, Kim, Tae Min, Ottmann, Oliver, Chromik, Joerg, Quinson, Anne-Marie, von Wangenheim, Ute, Burkard, Ute, Berk, Andreas, Schmitz, Norbert
Published in Investigational new drugs (01.02.2021)
Published in Investigational new drugs (01.02.2021)
Get full text
Journal Article
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma
Kroschinsky, Frank, Middeke, Jan Moritz, Janz, Martin, Lenz, Georg, Witzens-Harig, Mathias, Bouabdallah, Reda, La Rosée, Paul, Viardot, Andreas, Salles, Gilles, Kim, Seok Jin, Kim, Tae Min, Ottmann, Oliver, Chromik, Joerg, Quinson, Anne-Marie, von Wangenheim, Ute, Burkard, Ute, Berk, Andreas, Schmitz, Norbert
Published in Investigational new drugs (01.02.2021)
Published in Investigational new drugs (01.02.2021)
Get full text
Journal Article
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males
Burkard, Ute, Desch, Michael, Shatillo, Yury, Wunderlich, Glen, Mack, Salome Rebecca, Schlecker, Christina, Teitelbaum, Aaron M., Liu, Pingrong, Chan, Tom S.
Published in Clinical drug investigation (01.01.2022)
Published in Clinical drug investigation (01.01.2022)
Get full text
Journal Article
Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]‑BI 425809 in Healthy Males
Burkard, Ute, Desch, Michael, Shatillo, Yury, Wunderlich, Glen, Mack, Salome Rebecca, Schlecker, Christina, Teitelbaum, Aaron M., Liu, Pingrong, Chan, Tom S.
Published in Clinical drug investigation (01.04.2022)
Published in Clinical drug investigation (01.04.2022)
Get full text
Journal Article
Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors
Aftimos, Philippe Georges, Bechter, Oliver, Awada, Ahmad, Jungels, Christiane, Dumez, Herlinde, Huyvaert, Nathalie, Costermans, Jo, Lee, Chooi, Meeus, Marie-Anne, Burkard, Ute, Musa, Hanny, Zhao, Yihua, Schoffski, Patrick
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article